Industrial Policy & Trade Monitor· 2666 actions· ✨ 90 recent

On 2 April 2026 President Trump issued a Presidential Proclamation under Section 232 of the Trade Expansion Act of 1962 ("Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States") imposing a 100% ad valorem tariff on imports of patented pharmaceutical products listed in the FDA Orange Book and Purple Book, together with the active pharmaceutical ingredients (APIs) and key starting materials used to make them. The base rate takes effect at 12:01 a.m. EDT on 31 July 2026 for the 17 manufacturers identified in Annex III, and on 29 September 2026 for all other companies. The proclamation adopts findings of the Section 232 investigation initiated by the Department of Commerce on 14 April 2025 into pharmaceuticals and APIs as a national- security supply-chain risk. The instrument is structured around a multi-tier rate ladder rather than a flat tariff: concessionary 15% rates for EU/Japan/South Korea/Switzerland/Liechtenstein under reciprocal-deal tracks, 10% for the UK with a pathway to 0% under the pending UK pharmaceutical agreement, a "+20%" surcharge for companies operating under a Commerce-approved onshoring plan (until 2 April 2030), and a 0% pathway for companies that combine an approved onshoring plan with an MFN-pricing agreement with HHS (until 20 January 2029). Generics, biosimilars and their ingredients, orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, and cell/gene therapies are carved out.

Premier Li Qiang signed State Council Decree No. 792 on 19 October 2024 promulgating the Regulations of the People's Republic of China on Export Controls for Dual-Use Items, with effect from 1 December 2024. The regulation, organised in six chapters and 50 articles, consolidates the previously fragmented nuclear / biological / chemical / missile dual-use control regimes into a single State Council framework operationalising the 2020 Export Control Law. It introduces a control-list / temporary-control / watchlist architecture, a statutory end-user / end-use commitment regime, transit / transhipment / re-export controls, extraterritorial reach over PRC items downstream, and explicit linkage to the Anti-Foreign Sanctions Law. On 15 November 2024 MOFCOM, MIIT, GAC and SCA jointly issued Announcement No. 51 of 2024 publishing the consolidated Dual-Use Items Export Control List with a unified five-character ECCN-style coding system, also effective 1 December 2024.

The modern French FDI-screening regime is codified in Code monétaire et financier (CMF) Art. L151-1 to L151-7, substantially restructured by Loi PACTE n° 2019-486 du 22 mai 2019 (Art. 152-158) and operationalised by Décret n° 2019-1590 du 31 décembre 2019 (in force 1 April 2020) with implementing Arrêté du 31 décembre 2019. The regime requires prior authorisation from DG Trésor for non-EU/EEA acquisitions reaching ≥25% of a French target's voting rights across 17 sensitive sectors enumerated in CMF Art. R151-3, and for ≥10% acquisitions in listed-company targets (threshold made permanent by Décret 2023-1293 from 1 January 2024, having been originally introduced during COVID-19 by Décret 2020-892). Approximately 310 notifications are received annually; the regime closes the last major G7 EU-member-state FDI-screening parent-statute gap after DE AWG §§55-62, IT Golden Power DL 21/2012, NL Wet Vifo, UK NSI Act 2021, US CFIUS, JP FEFTA, AU FATA, and CH IPG.

Germany's Außenwirtschaftsgesetz (AWG, Foreign Trade and Payments Act; BGBl. I 2013 S. 1482 of 6 June 2013, replacing the original 1961 Act) is the foundational parent statute of the modern German economic-statecraft toolkit, providing the legislative authority for (i) export licensing of dual-use goods and technology administered by BAFA under the Außenwirtschaftsverordnung (AWV) implementing regulation — the national complement to EU Dual-Use Recast Regulation 2021/821; (ii) inward FDI screening by BMWK under §§ 55–62 AWG covering non-EU/non-EFTA acquisitions of ≥ 25% of voting rights cross-sectorally and ≥ 10%/20% in 27 sensitive-sector activities including defence, semiconductors, AI, quantum, biotech, space, and critical infrastructure; and (iii) German implementation of EU-level and autonomous trade and sanctions restrictions. As the EU's largest economy and a top-tier dual-use exporter, Germany's AWG-based regime is structurally peer-foundational to JP FEFTA 1949, UK NSI Act 2021, US ECRA 2018, CN Export Control Law 2020, and NL Wet Vifo 2022 in the G7+CN economic- statecraft parent-statute cluster.

The Tariff Act of 1930 (Pub. L. 71-361, 46 Stat. 590, codified principally at 19 U.S.C. Chapter 4) is the foundational US statute governing customs revenue, tariff classification, and trade-remedy administration, signed by President Hoover on 17 June 1930. The Act's original Smoot-Hawley tariff schedules are widely cited as a contributing factor to the contraction of global trade during the Great Depression, but the statute's enduring significance lies in its creation of (i) the Title VII antidumping (AD) and countervailing duty (CVD) proceedings framework administered jointly by Commerce ITA and the USITC — the parent authority for every US AD/CVD order in force today — and (ii) Section 337 (19 U.S.C. §1337), the USITC unfair-import and IP-exclusion-order regime under which ~50+ active investigations are conducted annually against semiconductor, biotech, electronics, and other technology imports. Title I's customs-valuation and HTSUS tariff- classification framework underpins all US import-revenue collection; Title VII AD/CVD authority was updated by the GATT Tokyo Round Trade Agreements Act of 1979 and the Uruguay Round Agreements Act of 1994 (URAA) to align with WTO Antidumping and Subsidies Agreements.